StonvexLoading…
StonvexStonvexStonvexCore line items from HBIO's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $86.55M | $94.14M | $112.25M | $113.33M |
Operating Income | $-48.58M | $-6.21M | $1.89M | $-6.93M |
Net Income | $-56.70M | $-12.40M | $-3.42M | $-9.52M |
EPS (Diluted) | $-1.28 | $-0.28 | $-0.08 | $-0.23 |
Total Assets | $80.07M | $126.64M | $137.37M | $145.36M |
Total Liabilities | $66.34M | $63.30M | $64.29M | $73.14M |
Cash & Equivalents | $8.61M | $4.11M | $4.28M | $4.51M |
Free Cash Flow OCF − CapEx | $5.47M | $-1.20M | $12.24M | $-438.00K |
Shares Outstanding | 44.72M | 44.07M | 43.39M | 42.08M |